Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, talks about what he sees in the future of suprachoroidal administration and other unmet needs in ophthalmology.
Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, talks about what he sees in the future of suprachoroidal administration and other unmet needs in ophthalmology.
Transcript
What else do you see in the future for suprachoroidal administration?
This is a really exciting time when we think about drug delivery, and there are a number of studies that are underway looking at suprachoroidal drug delivery for other indications. After its FDA approval for the treatment of uveitis, it's also being studied for other conditions, including diabetic retinopathy, macular degeneration, [and] tumors that affect the eye. As we understand the medication's efficacy and its safety signals for other indications, I see a future in suprachoroidal drug delivery for a number of retinal disease conditions, as well as ocular inflammation.
This is the first FDA-approved medication where medication is being delivered into the suprachoroidal space. Uveitis, as we know, is a vision-threatening disease indication and the visual acuity benefits, as well as the benefits to the anatomy of the eye, were really substantial and benefit patients both in terms of visual acuity and in terms of quality of life. So we're really excited about this technology and how it looks in the clinic in the future.
What are some other unmet needs in ophthalmology?
As we know that suprachoroidal delivery is effective for the treatment of non-infectious uveitis and, in particular, retinal swelling associated with non-infectious uveitis, we're going to continue to use this technique in other indications. So it's important that we continue to look at clinical trial data for the other indications where suprachoroidal drug delivery is being explored, including retinal disease conditions that are more common, such as age-related macular degeneration, diabetes, ocular tumors, and potentially disease-specific outcomes within the realm of intraocular inflammation and uveitis. There are other unmet needs certainly in the field of retina and uveitis care, and so we look forward to these results in the future.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More